Yaru Xu
Associate Research ScientistAbout
Research
Publications
2026
HOX code–based stratification reveals RUNX1T1–HDAC reprogramming as a targetable driver of lineage plasticity across cancers
Jiang Y, Cheng S, Zhang C, Jin X, Li L, Shin H, Alrefai A, Luo A, Xu Y, Kim I, Mu P. HOX code–based stratification reveals RUNX1T1–HDAC reprogramming as a targetable driver of lineage plasticity across cancers. Cancer Letters 2026, 648: 218465. PMID: 41912135, DOI: 10.1016/j.canlet.2026.218465.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsThis study investigates how HOX gene expression patterns identify therapy-resistant cancer subtypes and demonstrates RUNX1T1-HDAC3 inhibition as a potential treatment strategy for aggressive cancers.
2025
Androgen Deprivation-Induced TET2 Activation Fuels Prostate Cancer Progression via Epigenetic Priming and Slow-Cycling Cancer Cells.
Li L, Cheng S, Xu Y, Deng S, Mu P, Yu X. Androgen Deprivation-Induced TET2 Activation Fuels Prostate Cancer Progression via Epigenetic Priming and Slow-Cycling Cancer Cells. BioRxiv 2025 PMID: 40196510, DOI: 10.1101/2025.03.26.645495.Peer-Reviewed Original Research
2024
ZNF397 Deficiency Triggers TET2-driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer
Xu Y, Yang Y, Wang Z, Sjostrom M, Jiang Y, Tang Y, Cheng S, Deng S, Wang C, Gonzalez J, Johnson N, Li X, Li X, Metang L, Mukherji A, Xu Q, Tirado C, Wainwright G, Yu X, Barnes S, Hofstad M, Chen Y, Zhu H, Hanker A, Raj G, Zhu G, He H, Wang Z, Arteaga C, Liang H, Feng F, Wang Y, Wang T, Mu P. ZNF397 Deficiency Triggers TET2-driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer. Cancer Discovery 2024, 14: 1496-1521. PMID: 38591846, PMCID: PMC11285331, DOI: 10.1158/2159-8290.cd-23-0539.Peer-Reviewed Original Research
2023
UBE2J1 is the E2 ubiquitin-conjugating enzyme regulating androgen receptor degradation and antiandrogen resistance
Rodriguez Tirado C, Wang C, Li X, Deng S, Gonzalez J, Johnson N, Xu Y, Metang L, Sundar Rajan M, Yang Y, Yin Y, Hofstad M, Raj G, Zhang S, Lemoff A, He W, Fan J, Wang Y, Wang T, Mu P. UBE2J1 is the E2 ubiquitin-conjugating enzyme regulating androgen receptor degradation and antiandrogen resistance. Oncogene 2023, 43: 265-280. PMID: 38030789, PMCID: PMC10798893, DOI: 10.1038/s41388-023-02890-5.Peer-Reviewed Original ResearchLoss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer
Li X, Wang Y, Deng S, Zhu G, Wang C, Johnson N, Zhang Z, Tirado C, Xu Y, Metang L, Gonzalez J, Mukherji A, Ye J, Yang Y, Peng W, Tang Y, Hofstad M, Xie Z, Yoon H, Chen L, Liu X, Chen S, Zhu H, Strand D, Liang H, Raj G, He H, Mendell J, Li B, Wang T, Mu P. Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer. Cancer Cell 2023, 41: 1427-1449.e12. PMID: 37478850, PMCID: PMC10530398, DOI: 10.1016/j.ccell.2023.06.010.Peer-Reviewed Original Research
2022
Author Correction: Ectopic JAK–STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance
Deng S, Wang C, Wang Y, Xu Y, Li X, Johnson N, Mukherji A, Lo U, Xu L, Gonzalez J, Metang L, Ye J, Tirado C, Rodarte K, Zhou Y, Xie Z, Arana C, Annamalai V, Liu X, Vander Griend D, Strand D, Hsieh J, Li B, Raj G, Wang T, Mu P. Author Correction: Ectopic JAK–STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance. Nature Cancer 2022, 3: 1271-1271. PMID: 36241729, PMCID: PMC9586863, DOI: 10.1038/s43018-022-00458-y.Commentaries, Editorials and LettersEctopic JAK–STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance
Deng S, Wang C, Wang Y, Xu Y, Li X, Johnson N, Mukherji A, Lo U, Xu L, Gonzalez J, Metang L, Ye J, Tirado C, Rodarte K, Zhou Y, Xie Z, Arana C, Annamalai V, Liu X, Vander Griend D, Strand D, Hsieh J, Li B, Raj G, Wang T, Mu P. Ectopic JAK–STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance. Nature Cancer 2022, 3: 1071-1087. PMID: 36065066, PMCID: PMC9499870, DOI: 10.1038/s43018-022-00431-9.Peer-Reviewed Original Research
2018
The characterization and potential roles of bone morphogenetic protein 7 during spermatogenesis in Chinese mitten crab Eriocheir sinensis
Xu Y, Wang G, Zhou Y, Yang W. The characterization and potential roles of bone morphogenetic protein 7 during spermatogenesis in Chinese mitten crab Eriocheir sinensis. Gene 2018, 673: 119-129. PMID: 29890312, DOI: 10.1016/j.gene.2018.06.020.Peer-Reviewed Original ResearchRoles of three Es-Caspases during spermatogenesis and Cadmium-induced apoptosis in Eriocheir sinensis
Xu Y, Yang W. Roles of three Es-Caspases during spermatogenesis and Cadmium-induced apoptosis in Eriocheir sinensis. Aging 2018, 10: 1146-1165. PMID: 29851651, PMCID: PMC5990378, DOI: 10.18632/aging.101454.Peer-Reviewed Original ResearchThe role of FSH and TGF-β superfamily in follicle atresia
Chu Y, Xu Y, Yang W, Sun Y. The role of FSH and TGF-β superfamily in follicle atresia. Aging 2018, 10: 305-321. PMID: 29500332, PMCID: PMC5892684, DOI: 10.18632/aging.101391.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
News
News
- July 15, 2026
Urology Care Foundation Presents Awards to Cheng and Xu
- May 29, 2026
Yale Urology Engages on the Global Stage
- April 15, 2025
Yale Urology Research [Q1: January-March 2025]
- November 22, 2024
Yale Urology Adds to Oncology Section